CA2124329C - Composes, compositions et methodes de fixation de substances bio-actives aux membranes de surface de bio-particules - Google Patents

Composes, compositions et methodes de fixation de substances bio-actives aux membranes de surface de bio-particules Download PDF

Info

Publication number
CA2124329C
CA2124329C CA002124329A CA2124329A CA2124329C CA 2124329 C CA2124329 C CA 2124329C CA 002124329 A CA002124329 A CA 002124329A CA 2124329 A CA2124329 A CA 2124329A CA 2124329 C CA2124329 C CA 2124329C
Authority
CA
Canada
Prior art keywords
compound
alkyl
compounds
formula
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002124329A
Other languages
English (en)
Other versions
CA2124329A1 (fr
Inventor
Gregory A. Kopia
Paul K. Horan
Brian D. Gray
David E. Troutner
Katharine A. Muirhead
Lin Chia-En
Kamleshkumar A. Sheth
Zhizhou Yu
Susan Z. Lever
Kwamena E. Baidoo
Bruce D. Jensen
Sue E. Slezak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zynaxis Technologies Inc
Original Assignee
Zynaxis Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/884,432 external-priority patent/US5667764A/en
Application filed by Zynaxis Technologies Inc filed Critical Zynaxis Technologies Inc
Publication of CA2124329A1 publication Critical patent/CA2124329A1/fr
Application granted granted Critical
Publication of CA2124329C publication Critical patent/CA2124329C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1258—Pills, tablets, lozenges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA002124329A 1991-11-27 1992-11-24 Composes, compositions et methodes de fixation de substances bio-actives aux membranes de surface de bio-particules Expired - Lifetime CA2124329C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79893691A 1991-11-27 1991-11-27
US798,936 1991-11-27
US07/884,432 US5667764A (en) 1988-05-02 1992-05-15 Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
US884,432 1992-05-15
PCT/US1992/010076 WO1993011120A1 (fr) 1991-11-27 1992-11-24 Composes, compositions et procedes permettant de lier des substances bio-actives aux membranes de surface de bio-particules

Publications (2)

Publication Number Publication Date
CA2124329A1 CA2124329A1 (fr) 1993-06-10
CA2124329C true CA2124329C (fr) 2008-11-18

Family

ID=27122052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002124329A Expired - Lifetime CA2124329C (fr) 1991-11-27 1992-11-24 Composes, compositions et methodes de fixation de substances bio-actives aux membranes de surface de bio-particules

Country Status (10)

Country Link
EP (1) EP0643706A1 (fr)
JP (2) JP3682974B2 (fr)
CN (1) CN1074911A (fr)
AU (2) AU3221993A (fr)
CA (1) CA2124329C (fr)
IL (1) IL103874A0 (fr)
MX (1) MX9206844A (fr)
NZ (1) NZ245271A (fr)
PH (1) PH31676A (fr)
WO (1) WO1993011120A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
AU7476894A (en) * 1993-07-29 1995-02-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
US5480901A (en) * 1994-10-07 1996-01-02 Zynaxis, Inc. Method for reducing unwanted cellular adhesions
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US6004536A (en) * 1995-11-14 1999-12-21 Molecular Probes, Inc. Lipophilic cyanine dyes with enchanced aqueous solubilty
WO1997024459A1 (fr) * 1995-12-29 1997-07-10 Phanos Technologoes, Inc. Procede pour reduire les adherences cellulaires non desirees
US5871436A (en) * 1996-07-19 1999-02-16 Advanced Cardiovascular Systems, Inc. Radiation therapy method and device
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
JP2001521503A (ja) * 1997-03-31 2001-11-06 ネオルックス コーポレイション 血管平滑筋細胞の治療的阻害物質
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7045305B1 (en) * 1998-04-08 2006-05-16 The Regents Of The University Of California Methods and reagents for targeting organic compounds to selected cellular locations
PT1019111E (pt) 1998-04-27 2002-10-31 Surmodics Inc Revestimento que liberta um agente bioactivo
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
EP1218570A1 (fr) * 1999-08-23 2002-07-03 Angiogene, Inc. Dispositif a revetement radioactif et procede de fabrication de ce dernier destine a empecher la restenose
CO5261573A1 (es) 1999-11-19 2003-03-31 Novartis Ag Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
IT1319168B1 (it) * 2000-03-17 2003-09-26 Indena Spa Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.
EP1582180B1 (fr) 2000-10-16 2008-02-27 Conor Medsystems, Inc. Dispositif médical extensible pour delivrance d'un médicament
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US7776529B2 (en) 2003-12-05 2010-08-17 Life Technologies Corporation Methine-substituted cyanine dye compounds
CN1964749A (zh) 2004-04-06 2007-05-16 苏莫迪克斯公司 用于生物活性剂的涂料组合物
USD516723S1 (en) 2004-07-06 2006-03-07 Conor Medsystems, Inc. Stent wall structure
AU2005307195A1 (en) 2004-11-22 2006-05-26 Ge Healthcare As Contrast agents to target extracellular matrix
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
EP1885718B1 (fr) 2005-05-11 2017-03-15 Life Technologies Corporation Composes chimiques fluorescents possedant une selectivite elevee pour l'adn double brin, et procedes d'utilisation
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
CN105745266B (zh) * 2013-11-26 2019-05-17 住友化学株式会社 橡胶组合物及硫化助剂
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
EP3101012A1 (fr) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft Nouveaux composés de chélate de gadolinium pour une utilisation dans l'imagerie par résonance magnétique
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation
JP7423888B2 (ja) * 2019-11-22 2024-01-30 株式会社同仁化学研究所 脂質二分子膜染色用色素及びそれを用いた脂質二分子膜の染色方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE3170134D1 (en) * 1980-09-02 1985-05-30 Fuji Photo Film Co Ltd Method for immunochemical measurement
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
US4762701A (en) * 1986-10-31 1988-08-09 Smithkline Beckman Corporation In vivo cellular tracking
US4783401A (en) * 1986-10-31 1988-11-08 Smithkline Beckman Corporation Viable cell labelling
US4906749A (en) * 1987-06-30 1990-03-06 Viomedics Inc. Cyclic anhydride derivatives of chromophors
JPH03502327A (ja) * 1988-01-19 1991-05-30 ボード・オブ・リージェンツ，ザ・ユニバーシティ・オブ・テキサス・システム ３’‐デアミノドキソルビシンのエステル体、そのリポソーム組成物およびその使用方法
DE68927479T2 (de) * 1988-05-02 1997-04-03 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting

Also Published As

Publication number Publication date
CA2124329A1 (fr) 1993-06-10
EP0643706A4 (fr) 1994-12-27
WO1993011120A1 (fr) 1993-06-10
EP0643706A1 (fr) 1995-03-22
AU3221993A (en) 1993-06-28
JP2003026657A (ja) 2003-01-29
JP3682974B2 (ja) 2005-08-17
NZ245271A (en) 1996-03-26
MX9206844A (es) 1993-07-01
JP4095847B2 (ja) 2008-06-04
AU1991497A (en) 1997-07-10
CN1074911A (zh) 1993-08-04
IL103874A0 (en) 1993-04-04
JPH08502719A (ja) 1996-03-26
PH31676A (en) 1999-01-18

Similar Documents

Publication Publication Date Title
US5667764A (en) Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
JP4095847B2 (ja) バイオ作用性物質をバイオ粒子表面膜へ結合するための化合物、組成、および方法
EP0137457B1 (fr) Conjugués de métallothionéine et de molécules biologiquement actives chercheuses de cible, marqués par un traceur
DE69434086T2 (de) Herstellung und Verwendung von Immunkonjugaten die eine VL-Kette enthalten welche am Asn in Position 18 glykosyliert ist
KR100896983B1 (ko) 펩티드-기재 화합물
US5606028A (en) Anchimeric radiometal chelating compounds
AU7440400A (en) Methods and compositions for producing long lasting antineoplastic agents
EP0438497A1 (fr) Conjugues ameliorant la permeabilite vasculaire.
KR20020087973A (ko) 펩티드 기재 화합물
US5310536A (en) Ligands for improving metal chelate formation kinetics
JPH09506870A (ja) 金属キレート化剤
DE69330494T2 (de) Radioaktiv markierte somatostatin
EP0630264B1 (fr) Ligands permettant d'ameliorer la cinetique de formation d'agents chelateurs
CA2066031C (fr) Methodes de reduction de la retention non recherchee d'immunoconjugues et metabolites obtenus
Panwar et al. 99mTc-Tetraethylenepentamine-folate a new 99mTc based folate derivative for the detection of folate receptor positive tumors: synthesis and biological evaluation
US6696551B1 (en) 225Ac-HEHA and related compounds, methods of synthesis and methods of use
CA2092434A1 (fr) Agents chelateurs
EP0590766B1 (fr) Agents de chelation des acides aminocarboxyliques hydroxyaryl
US20250082797A1 (en) Methods for In Vivo Tracking of Cells
MXPA94003278A (es) Metodo para preparar una proteina marcada con radionuclido metalico.
STEINMANN et al. A novel methotrexate-albumin (MTX-RSA)-conjugate causes significant growth delay of O-342 ovarian-carcinoma in-vivo
EP1889639A2 (fr) Procédés et compositions pour produire des agents antinéoplastiques de très longue durée

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry